Regenerative medicine company CollPlant renewed its exclusive distribution agreement with Arthrex for its soft tissue repair product Vergenix STR.
Three things to know:
1. Vergenix STR is designed to treat tendinopathy. It is an injectable gel comprised of cross-linked bioengineered recombinant human type I collagen combined with autologous platelet-rich plasma. It is intended to form a collagen-fibrin matrix to serve as a scaffold for cell recruitment.
2. The original distribution agreement began in December 2016 and is now extended through Dec. 31, 2020, with Arthrex serving as the exclusive distributor in Europe, the Middle East, Asia and certain African countries.
3. "Leveraging on the post marketing surveillance clinical data, we now plan on expanding the distribution of Vergenix STR to other territories, including Asia," said CollPlant CEO Yehiel Tal.